Divisadero Street Capital Management LP acquired a new stake in shares of PetIQ, Inc. (NASDAQ:PETQ – Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 55,266 shares of the company’s stock, valued at approximately $1,219,000. Divisadero Street Capital Management LP owned approximately 0.19% of PetIQ as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its position in PetIQ by 11.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 1,036,292 shares of the company’s stock valued at $20,467,000 after acquiring an additional 108,870 shares in the last quarter. ProShare Advisors LLC boosted its position in PetIQ by 119.6% during the first quarter. ProShare Advisors LLC now owns 173,453 shares of the company’s stock valued at $3,171,000 after purchasing an additional 94,453 shares in the last quarter. Swiss National Bank purchased a new position in PetIQ in the fourth quarter valued at about $1,080,000. Los Angeles Capital Management LLC raised its holdings in PetIQ by 196.6% in the first quarter. Los Angeles Capital Management LLC now owns 129,632 shares of the company’s stock worth $2,370,000 after purchasing an additional 85,920 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC lifted its position in shares of PetIQ by 105.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 140,660 shares of the company’s stock valued at $2,571,000 after buying an additional 72,187 shares during the last quarter. 94.99% of the stock is owned by hedge funds and other institutional investors.
PetIQ Stock Performance
PETQ opened at $30.76 on Friday. The company has a market cap of $915.17 million, a P/E ratio of 139.91 and a beta of 1.73. The company has a quick ratio of 1.68, a current ratio of 2.58 and a debt-to-equity ratio of 1.68. The firm’s 50-day moving average price is $27.15 and its 200-day moving average price is $21.86. PetIQ, Inc. has a 52-week low of $15.09 and a 52-week high of $30.84.
Wall Street Analyst Weigh In
PETQ has been the subject of a number of analyst reports. Truist Financial cut shares of PetIQ from a “buy” rating to a “hold” rating and increased their target price for the company from $30.00 to $31.00 in a research report on Thursday, August 8th. William Blair lowered PetIQ from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 7th. Two analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $29.67.
Check Out Our Latest Stock Analysis on PETQ
About PetIQ
PetIQ, Inc operates as a pet medication and wellness company in the United States and internationally. It operates in two segments, Products and Services. The company offers Rx pet medications, which sells flea and tick control, heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics, and other specialty medications; and develops and manufactures its own proprietary value-branded products, as well as third-party branded products for dogs and cats.
Featured Stories
- Five stocks we like better than PetIQ
- What is MarketRank™? How to Use it
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- How to buy stock: A step-by-step guide for beginners
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- Buy P&G Now, Before It Sets A New All-Time High
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding PETQ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PetIQ, Inc. (NASDAQ:PETQ – Free Report).
Receive News & Ratings for PetIQ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetIQ and related companies with MarketBeat.com's FREE daily email newsletter.